Sponsors (2)
The bill aims to accelerate U.S. biotechnology research, commercialization, workforce development, and security through coordinated funding, centralized resources, and streamlined processes, but does so at the cost of higher federal spending, greater centralization of authority, reduced transparency, and added privacy and health‑safety risks if safeguards are not carefully enforced.
Scientists, universities, and research institutions receive sustained, coordinated federal funding, grants, and strategy guidance to accelerate biotechnology R&D and innovation.
Startups and small biotech firms gain clearer regulatory pathways, a single application portal, and greater access to SBIR/STTR, user facilities, and testbeds, reducing commercialization uncertainty and helping scale products.
Students, veterans, and workers receive new domestic biotech workforce pipelines and training programs that improve job prospects and skills for biotech careers.
Taxpayers face higher federal spending to support sustained R&D, data infrastructure, new permanent offices/staffing, testbeds, and commercialization incentives.
Patients, research subjects, hospitals, and the public face increased privacy and data‑security risks from expanded data collection and centralized biological data hubs and increased data‑sharing.
Patients, health systems, and the public may face greater health or environmental risks if regulatory streamlining and eased oversight reduce scrutiny of biotechnology products.
Based on analysis of 6 sections of legislative text.
Creates a White House-led National Biotechnology Initiative, an NBCO and interagency committee to coordinate federal biotech research, data, commercialization, biosecurity, and workforce efforts.
Introduced April 9, 2025 by Todd Young · Last progress April 9, 2025
Creates a coordinated National Biotechnology Initiative led from the White House to advance U.S. biotechnology research, commercialization, workforce development, biosafety/biosecurity, and data infrastructure. The law establishes an interagency committee and a National Biotechnology Coordination Office (NBCO) with a Director to advise the President and coordinate participating federal agencies. The bill directs participating agencies to appoint senior biotechnology leads, carry out a national biotechnology strategy, share expertise and data, support sustained R&D and commercialization (including joint solicitations and centers), assess foreign-adversary threats and supply-chain risks, improve biosecurity and data protections, and engage with industry and international partners. It also authorizes expert convenings exempt from the Federal Advisory Committee Act and sets 180-day deadlines to create the office and interagency committee.